RxDoctor Payments Data

Lisa Turk

Psychiatric/Mental Health · Whitehall, MTNPI 1962940460

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.7% of the total across 57 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 33.3% of the total. Reporting peaked in 2021 at $340 and has fallen 92.7% since, to $25 in 2025.

$740in general payments, 2019–2025

Across 57 payments — averaging $12.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$247
  • AbbVie$146
  • Sunovion Pharmaceuticals Inc.$101
  • Neurocrine Biosciences, Inc.$78
  • Teva Pharmaceuticals USA, Inc.$68
  • Vanda Pharmaceuticals Inc.$35
  • plus $65 from 3 others

What the payments were for

  • Food & beverage$69394%
  • Education$476%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$740 in reported general payments places this provider in the 85th percentile of 142 psychiatric/mental health providers in Montana.

See all psychiatric/mental health providers in Montana

Medicare billing

Part B allowed, 2024
$47,850
Medicare patients
32
Services billed
565

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate23$76,339
Lurasidone Hcl36$5,789
Aripiprazole38$2,798
Olanzapine82$2,274
Naltrexone Hcl18$1,609
Bupropion XlBupropion Hcl96$1,271
Quetiapine Fumarate97$1,037
Buspirone Hcl98$954
Fluoxetine Hcl81$952
Paliperidone ErPaliperidone11$747
Prazosin Hcl57$593
Hydroxyzine Pamoate40$561
Lamotrigine52$499
Propranolol Hcl28$385
Benztropine Mesylate40$381

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$30$76,33923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 142 psychiatric/mental health providers in Montana.

Other psychiatric/mental health in Whitehall

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →